With all the excitement around AI accelerating science in the next few years, it can be easy to lose sight of the impact models are having _today_ on some of the hardest challenges in the world's leading pharmaceutical companies. Chai-3 was a step-change for us and our partners. Excited to work with @bmsnews to chart new frontiers in medicine and science.
Frontier drug discovery programs require frontier capabilities. Today, we’re excited to share that BMS will be using Chai’s models to support the discovery of new therapeutics. Since rolling out Chai-3 to partners at the start of this year, we’ve partnered with @EliLillyandCo, @Novartis, @Pfizer, @argenxglobal, and now @BMSnews. Many of the world’s leading biopharma companies are now using our models to go after diseases.
Scientific discovery is the domain where access to frontier AI matters the most. At @ChaiDiscovery, we’ve seen first hand how our latest model generations can make the difference between discovering a molecule and not. We’re excited to work with @BMSnews to break new ground in medicine and science.
Tune in to @latentspacepod to hear @Mattmcpartlon1 and @realdealpatil talk about the transformational moment bio AI is going through, and why you don't need a background in biology to make an impact in the space.
To date, finding a drug has been a process of guess & check… screening millions of molecules hoping one binds.
@chaidiscovery is changing the paradigm… describe the molecule you want, and the model designs it.
@joshim5 and @Mattmcpartlon1 took antibody hit rates from roughly 1 in 1,000 to 1 in 7. That's the jump from search to engineering.
On this episode of Training Data, they get into where the field actually is, why 2024 was the moment to start, what drug discovery looks like when the computer does the design, and more.
00:00 Introduction
01:52 From Discovery to Design
03:25 Protein AI Breakthroughs Timeline
06:04 Why Start in 2024
10:13 Diffusion Models Intuition
11:41 Building the Avengers Team
15:22 Hit Rates and Scaling Laws
25:01 Molecular CAD Vision
25:24 Faster Design Loops
26:32 Future Drug Discovery
28:37 Platform Business Model
31:14 Partnering Reality Check
33:44 Data Flywheel Explained
37:16 Staying Ahead at Scale
39:44 Culture and What's Next
Exclusive: Inside $3.8B @chaidiscovery
After leaving OpenAI & Stripe, co-founders Josh Meier (@joshim5) and Jack Dent (@jackdent) built a pioneering AI drug design model called Chai-1. Now? Their models are used by giants like Eli Lilly, Pfizer and Novartis.
Their models design antibodies in hours, not years - with atomic-level accuracy confirmed in the lab. If they're right, we're closer than ever to curing complex diseases. We went to San Francisco to find out.
They've raised $600M + from @saranormous@lachygroom@FEhrsam@ThriveCapital@sequoia@generalcatalyst@OpenAI@MenloVentures@IndexVentures@kleinerperkins + more.
0:00 AI drug design - how is it possible?
1:32 Josh: Leaving OpenAI for biology
2:34 90% of drugs used to fail
3:24 An outside scientist's honest take
4:40 Chai-3: Drug design in hours not years
5:30 Why Eli Lilly bet on Chai
6:20 When will this reach patients?
8:56 A hopeful future: Alzheimer's & aging
applications for Embed now open, due 8/10
Embed is a Schelling Point for the best early stage founders. cash, compute, community, & a catalyst
past participants were dropouts, leading researchers and repeat founders
alumni have raised more than a billion dollars
links in🧵
we gave @colossusmag a look at what @mvernal@pranavreddy@igarciacamargo me & team @conviction are trying to do — find and arm the most extraordinary founders at a moment when technology molds a malleable future
feels like a mission! but yes, acting with belief is also a wager
What a week at @chaidiscovery.
In the last 3 days:
- Unveiled our collaboration with @Novartis
- Announced our $400M Series C
- A new agreement with @argenxglobal
We’re delighted to announce our third agreement this week, this time a collaboration with @argenxglobal.
argenx has built one of biotechnology’s most productive antibody engines. We’ll be putting Chai’s frontier molecular design platform into the hands of their scientists.
Thank you @tbpn for having me on to talk about the breathtaking pace of model development in AI<>bio, just how large the pharma industry is (sneak peek: even bigger than the chip industry, by revenue), and our Series C.
Chai Discovery cofounder @jackdent says AI drug discovery hit a major inflection point in 2025.
As a result, it's now being deployed at the biggest pharma companies as part of their core discovery engines.
"Over the course of 2025, these models went from being research curiosities... to being able to design molecules without needing to fine-tune them on a lot of data."
"You can really just prompt them in the way that you'd prompt an LLM with a target, maybe some disease you're going after. And they will design a number of candidates that would help do that, essentially."
"A year, year and a half ago, basically none of this stuff worked."
"In 2025 we really crossed the Rubicon. And now these technologies are actively being deployed in companies like Eli Lilly, Novartis, Pfizer. These are some of the most scientific, highest-tech companies in the world. And they're putting them into real drug programs and making them part of their core discovery engines."
@AndrewGSugrue@joshim5@AndrewGSugrue the quality of your research, conviction, and founder-orientation are second to none. Thank you for being such amazing partners.